Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia

Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia

Abstract Background Fluoropyrimidines (FP) are among the most common class of prescribed anti‐neoplastic drugs. This class has severe to moderate toxicity in around 10%–40% of those who take 5‐fluorouracil (5‐FU) or capecitabine for the treatment of cancer. In practice many patients with severe toxi...

Full description

Bibliographic Details
Main Authors: Hatouf H. Sukkarieh, Turki AlSagoor, Mohammed Alnuhait, Rami Bustami, Scott Bryson, Fatima Mohammed Kebir Adem, Hana Abdalla, Gulsan Karbani
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Reports
Subjects:
5‐fluorouracil
capecitabine
dihyropyrimidine dehydrogenase deficiency
fluoropyrimidines
personalized medicine
pharmacogenomics
Online Access:https://doi.org/10.1002/cnr2.1704

Internet

https://doi.org/10.1002/cnr2.1704

Similar Items